BAL PHARMA LTD. - 524824 - Compliance With Regulation 7(3) Of SEBI(LODR) Regulations.
Compliance certificate as per Regulation 7(3) of SEBI(LODR) Regulations for the half year ended 31.03.2022.06-04-2022
06-04-2022
BAL PHARMA LTD. - 524824 - Board Meeting Intimation for Allotment Of Equity Shares Upon Conversion Of Warrants.
BAL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/04/2022 ,inter alia, to consider and approve allotment of equity shares to the beneficiaries who have exercised the conversion option on the warrants allotted to them on preferential basis.05-04-2022
BAL PHARMA LTD. - 524824 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Based on the certificate's received from our R&T agents i.e TSR Darashaw Pvt Ltd, we would like to confirm that the details of securities dematerialized / rematerialized during the quarter ended on 31.03.2022 have been furnished to all the stock exchanges where the equity shares of the Company are listed, within the prescribed time limit. The Share certificates received for dematerialization, if any has been mutilated and cancelled after due verification and the name of the depository has been substituted in the records as registered owner, within 15 days of the receipt of the certificate of security.04-04-2022
BAL PHARMA LTD. - 524824 - Statement Of Investor Complaints For The Quarter Ended March 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- G RenagarajanDesignation :- Chief Financial Officer04-04-2022
BAL PHARMA LTD. - 524824 - Closure of Trading Window
Pursuant to the Code of conduct of the Company and as per the amended provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015, we wish to inform the exchange that the trading window for dealing with the securities of the Company on the designated employees and their relatives will be closed from 1st April 2022 and up to 48 hours of the declaration of the audited financial results of the Company, for the quarter and financial year ended 31/03/2022. The date of the Board meeting for declaration of the audited financial results, will be intimated to the exchange in due course.31-03-2022
BAL PHARMA LTD. - 524824 - Board Meeting Outcome for Out Come Of The Board Meeting-Approval For Amalgamation Of Golden Drugs Pvt Ltd With Bal Pharma Ltd.
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company at its meeting held on 9th March, 2022, has considered and approved the Scheme of Merger (the "Scheme") pursuant to Sections 230 to 232 and other applicable provisions of the Companies Act, 2013, if any, providing for the merger of its wholly owned subsidiary- Golden Drugs Private Limited ("Transferor Company") with Bal Pharma Limited ("Transferee Company"). The Scheme would be implemented subject to the requisite statutory / regulatory approvals including the approval of the National Company Law Tribunal (Bengaluru Bench). The Company will be filing joint application with Hon'ble National Company Law Tribunal (Bengaluru Bench) in due course of time to obtain approval on the scheme as required under the provisions of the Companies Act, 2013.09-03-2022
BAL PHARMA LTD. - 524824 - Board Meeting Intimation for Approval Of Scheme Of Amalgamation.
BAL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/03/2022 ,inter alia, to consider and approve The meeting of Board of Directors of the Company is scheduled to be held on 9.03.2022 i.e on Wednesday to inter alia consider approval of scheme of amalgamation between Bal Pharma Ltd and its wholly owned subsidiary i.e Golden Drugs Private Ltd , subject to the approval of applicable statutes and shareholders of the Company.28-02-2022
BAL PHARMA LTD. - 524824 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
We are submitting to the exchange notices received from our R&T agents i.e TSR Darashaw Private Ltd, Mumbai, regarding loss of share certificates by one of our share holder.25-02-2022
BAL PHARMA LTD. - 524824 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press release on revision of credit ration.24-02-2022
BAL PHARMA LTD. - 524824 - Announcement under Regulation 30 (LODR)-Credit Rating
ACUITE has upgraded the credit ratings of the Company, as follows. 01. Long Term Fund based facilities Upgraded to ACUITE BBB- stable from (ICRA) BB+ positive. 02. Short term Non fund based facilities Upgraded to ACUITE A3 from (ICRA) A4+ . 03. Long term-Term Loan Upgraded to ACUITE BBB- stable from (ICRA) BB+ positive.22-02-2022